DMAA Stock — Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

Updated October 16, 2026.

DMAA is a Stock. Total return is 9.1% over the past 1.6 years, 21.9 points behind SPY at 31.0%.

Drugs Made In America Acquisition Corp. is a newly incorporated blank-check company with no current operations that intends to pursue a merger, share exchange, asset acquisition, or similar business combination with one or more operating businesses. The company does not currently distribute to shareholders. This security appeals primarily to investors seeking exposure to potential future business combinations in the pharmaceuticals or healthcare sector, though the ultimate business direction and investment characteristics remain undetermined pending completion of a business combination.

DMAA performance versus SPY

Price and return data through 2026-10-16.

Total return is 9.1% over the past 1.6 years, 21.9 points behind SPY at 31.0%. Over the past year its total return — price change plus distributions reinvested — is 5.4%. Its deepest 1-year drawdown was 0.5%.

DMAA key facts

Asset type

Stock

Asset class

Equity

Inception date

02/25/2025

Distribution frequency

None

Last close

$10.87 (as of 2026-10-16)

Market cap

$263,890,044

Average volume

794.0

Beta

0.0021

Payout ratio

0.0%

P/E ratio

60.39

EPS

$0.18

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DMAA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 0.5%.

Who may consider DMAA — and who may not

It is a weaker fit for investors who need monthly cash flow (DMAA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DMAA

• All tickers starting with D

Tagged: Financials.

Frequently asked questions